Equities researchers at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
TTNP opened at $4.14 on Thursday. The stock’s 50-day moving average price is $3.45 and its 200 day moving average price is $4.51. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- What is the Shanghai Stock Exchange Composite Index?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Golden Cross Stocks: Pattern, Examples and Charts
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
